Advertisement

Archives of Pharmacal Research

, Volume 41, Issue 2, pp 196–207 | Cite as

Dihydroxanthyletin-type coumarins from Angelica decursiva that inhibits the formation of advanced glycation end products and human recombinant aldose reductase

Research Article

Abstract

The formation of advanced glycation end-products (AGE) and aldose reductase activity have been implicated in the development of diabetic complications. The present study was aimed to evaluate human recombinant aldose reductase (HRAR) and AGE inhibitory activity of seven natural dihydroxanthyletin-type coumarins, 4-hydroxy Pd-C-III (1), 4′-methoxy Pd-C-I (2), Pd-C-I (3), Pd-C-II (4), Pd-C-III (5), decursidin (6), and (+)-trans-decursidinol (7) from Angelica decursiva. Coumarins 1–7 showed potent HRAR and AGE inhibitory activities with ranges of IC50 values of 1.03–21.31 and 0.41–5.56 µM, respectively. In the kinetic study for HRAR enzyme inhibition, coumarins 1, 3, 4, and 7 were competitive-type inhibitors, 6 was a mixed-type inhibitor, whereas 2 and 5 were noncompetitive-type inhibitors. Furthermore, we also predicted the docking interactions of HRAR with coumarins 1–7 using AutoDock Vina, and as a result, the simulated enzyme-inhibitor complexes exhibited negative binding energies (Autodock Vina = − 9.6 to − 8.1 kcal/mol for HRAR), indicating a high affinity and tight binding capacity for the HRAR active site. Our results clearly indicate the potential HRAR and AGE formation inhibitory activities of dihydroxanthyletin-type coumarins, which could be further explored to develop therapeutic modalities for the treatment of diabetes and related complications.

Keywords

A. decursiva Advanced glycation end-products Human recombinant aldose reductase Diabetic complication Molecular docking 

Notes

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and funded by the Ministry of Science, ICT, and Future Planning (2014R1A1A3051684).

References

  1. Ahmed N (2005) Advanced glycation endproducts: role in pathology of diabetic complications. Diabetes Res Clin Pract 67:3–21CrossRefPubMedGoogle Scholar
  2. Ali MY, Jung HA, Choi JS (2015) Anti-diabetic and anti-Alzheimer’s disease activities of Angelica decursiva. Arch Pharm Res 38:2216–2227CrossRefGoogle Scholar
  3. Ali MY, Jannat S, Jung HA, Choi RJ, Roy A, Choi JS (2016a) Anti-Alzheimer potential of coumarins from Angelica decursiva and Artemisia capillaris and structure-activity analysis. Asian Pac J Trop Med 9:103–111CrossRefPubMedGoogle Scholar
  4. Ali MY, Jannat S, Jung HA, Jeong HO, Chung HY, Choi JS (2016b) Coumarins from Angelica decursiva inhibit α-glucosidase activity and protein tyrosine phosphatase 1B. Chem Biol Interact 252:93–101CrossRefPubMedGoogle Scholar
  5. Anand P, Singh B, Singh N (2012) A review on coumarins as acetylcholinesterase inhibitors for Alzheimer’s disease. Bioorg Med Chem 20:1175–1180CrossRefPubMedGoogle Scholar
  6. Aragno M, Mastrocola R (2017) Dietary sugars and endogenous formation of advanced glycation endproducts: emerging mechanisms of disease. Nutrients 9:385–401CrossRefPubMedCentralGoogle Scholar
  7. Asif M (2015) Pharmacologically potentials of different substituted coumarin derivatives. Chem Int 1:1–11Google Scholar
  8. Bairagi SH, Salaskar PP, Loke SD, Surve NN, Tandel DV, Dusara MD (2012) Medicinal significance of coumarins. Int J Pharm Res 4:16–19Google Scholar
  9. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefPubMedGoogle Scholar
  10. Byun K, Yoo YC, Son M, Lee J, Jeong GB, Park YM, Salekdeh GH, Lee B (2017) Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases. Pharmacol Ther 177:44–55CrossRefPubMedGoogle Scholar
  11. Chang WC, Wu SC, Xu KD, Liao BC, Wu JF, Cheng AS (2015) Scopoletin protects against methylglyoxal-induced hyperglycemia and insulin resistance mediated by suppression of advanced glycation endproducts (AGEs) generation and anti-glycation. Molecules 20:2786–2801CrossRefPubMedGoogle Scholar
  12. David RT, Gary BW, Anne UC (1992) Aldose reductase inhibitors and diabetic complications. Pharmacol Ther 54:151–194CrossRefGoogle Scholar
  13. de la Fuente JA, Manzanaro S (2003) Aldose reductase inhibitors from natural sources. Nat Prod Rep 20:243–251CrossRefPubMedGoogle Scholar
  14. El-Kabbani O, Podjarny A (2007) Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites. Cell Mol Life Sci 64:1970–1978CrossRefPubMedGoogle Scholar
  15. El-Kabbani O, Old SE, Ginell SL, Carper DA (1999) Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. Mol Vis 5:20–26PubMedGoogle Scholar
  16. Gao Q, Jeon SJ, Jung HA, Lee HE, Park SJ, Lee Y, Lee Y, Ko SY, Kim B, Choi JS, Ryu JH (2015) Nodakenin enhances cognitive function and adult hippocampal neurogenesis in mice. Neurochem Res 40:1438–1447CrossRefPubMedGoogle Scholar
  17. Gomez-Outes A, Suarez-Gea ML, Calvo-Rojas G, Lecumberri R, Rocha E, Pozo-Hernandez C, Terleira-Fernandez AI, Vargas-Castrillon E (2012) Discovery of anticoagulant drugs: a historical perspective. Curr Drug Discov Technol 9:83–104CrossRefPubMedGoogle Scholar
  18. Ishita IJ, Islam MN, Kim YS, Choi RJ, Sohn HS, Jung HA, Choi JS (2016) Coumarins from Angelica decursiva inhibit lipopolysacharide-induced nitric oxide production in RAW 264.7 cells. Arch Pharm Res 39:115–126CrossRefPubMedGoogle Scholar
  19. Islam MN, Choi RJ, Jin SE, Kim YS, Ahn BR, Zhao D, Jung HA, Choi JS (2012) Mechanism of anti-inflammatory activity of umbelliferone 6-carboxylic acid isolated from Angelica decursiva. J Ethnopharmacol 144:175–181CrossRefPubMedGoogle Scholar
  20. Jung HA, Islam MN, Kwon YS, Jin SE, Son YK, Park JJ, Sohn HS, Choi JS (2011) Extraction and identification of three major aldose reductase inhibitors from Artemisia montana. Food Chem Toxicol 49:376–384CrossRefPubMedGoogle Scholar
  21. Jung HA, Park JJ, Islam MN, Jin SE, Min BS, Lee JH, Sohn HS, Choi JS (2012) Inhibitory activity of coumarins from Artemisia capillaris against advanced glycation endproduct formation. Arch Pharm Res 35:1021–1035CrossRefPubMedGoogle Scholar
  22. Jung HA, Ali MY, Jannat S, Park SK, Choi JS (2017) Molecular docking study and evaluation of the anti-diabetic complications of dihydroxanthyletin-type coumarins from Angelica decursiva. FASEB J 31:646.37Google Scholar
  23. Kaneko M, Bucciarelli M, Hwang YC, Lee L, Yan SF, Schmidt AM, Ramasamy R (2005) Aldose reductase and AGE-RAGE pathway: key players in myocardial ischemic injury. Ann NY Acad Sci 1043:702–709CrossRefPubMedGoogle Scholar
  24. Kato A, Kobayashi K, Narukawa K, Minoshima Y, Adachi I, Hirono S, Nash RJ (2010) 6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2. Bioorg Med Chem Lett 20:5630–5633CrossRefPubMedGoogle Scholar
  25. Kim DH, Kim DY, Kim YC, Jung JW, Lee SJ, Yoon BH, Cheong JH, Kim YS, Kang SS, Ko KH, Ryu JH (2007) Nodakenin, a coumarin compound, ameliorates scopolamine-induced memory disruption in mice. Life Sci 80:1944–1950CrossRefPubMedGoogle Scholar
  26. Kim JH, Kim CS, Lee YM, Sohn E, Jo KH, Shin SD, Kim JS (2013) Scopoletin inhibits rat aldose reductase activity and cataractogenesis in galactose-fed rats. Evid Based Complement Altern Med 2013:1–8Google Scholar
  27. Kim CS, Kim JH, Lee YM, Sohn E, Kim JS (2016) Esculetin, a coumarin derivative, inhibits aldose reductase activity in vitro and cataractogenesis in galactose-fed rats. Biomol Ther 24:178–183CrossRefGoogle Scholar
  28. Kim SB, Hwang SH, Wang Z, Yu JM, Lim SS (2017) Rapid identification and isolation of inhibitors of rat lens aldose reductase and antioxidant in Maackia amurensis. BioMed Res Int 2017:1–10Google Scholar
  29. Kinoshita T, Miyake H, Fujii T, Takakura S, Goto T (2002) The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat. Acta Crystallogr D 58:622–626CrossRefPubMedGoogle Scholar
  30. Kontogiorgis C, Detsi A, Hadjipavlou-Litina D (2012) Coumarin-based drugs: a patent review (2008–present). Expert Opin Ther Patents 22:437–454CrossRefGoogle Scholar
  31. Lee SW, Kim CS, Cho SH, Chun HS, Kim JK, Kim DK (2009) The effects of Angelica decursiva extract in the inhibition of cell proliferation and in the induction of apoptosis in osteogenic sarcoma cells. J Med Plant Res 3:241–245Google Scholar
  32. Leu YL, Chen YW, Yang CY, Huang CF, Lin GH, Tsai KS, Yang RS, Liu SH (2009) Extract isolated from Angelica hirsutiflora with insulin secretagogue activity. J Ethnopharmacol 123:208–212CrossRefPubMedGoogle Scholar
  33. Lim HJ, Lee JH, Choi JS, Lee SK, Kim YS, Kim HP (2014) Inhibition of airway inflammation by the roots of Angelica decursiva and its constituent, columbianadin. J Ethnopharmacol 155:1353–1361CrossRefPubMedGoogle Scholar
  34. Makita Z, Radoff S, Rayfield EJ, Yang ZH, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara HN (1993) Advanced glycosylation end products in patients with diabetic nephropathy. N Eng J Med 325:836–842CrossRefGoogle Scholar
  35. Manivannan A, Soundararajan P, Park YG, Sakkiah S, Jeong BR (2015) Binding mode investigation of polyphenols from Scrophularia targeting human aldose reductase using molecular docking and molecular dynamics simulations. J Chem 2015:1–12CrossRefGoogle Scholar
  36. Pari L, Rajarajeswari N (2009) Efficacy of coumarin on hepatic key enzymes of glucose metabolism in chemical induced type 2 diabetic rats. Chem Biol Interact 181:292–296CrossRefPubMedGoogle Scholar
  37. Peyroux J, Sternberg M (2006) Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol 54:405–419CrossRefPubMedGoogle Scholar
  38. Ramesh B, Pugalendi KV (2007) Effect of umbelliferone on tail tendon collagen and haemostatic function in streptozotocin diabetic rats. Basic Clin Pharmacol Toxicol 101:73–77CrossRefPubMedGoogle Scholar
  39. Rehman S, Ikram M, Baker RJ, Zubair M, Azad E, Min S, Riaz K, Mok KH, Rehman SU (2013) Synthesis, characterization, in vitro antimicrobial, and U2OS tumoricidal activities of different coumarin derivatives. Chem Cent J 7:68–79CrossRefPubMedPubMedCentralGoogle Scholar
  40. Sarkanj B, Molnar M, Cacic M, Gille L (2013) 4-Methyl-7-hydroxycoumarin antifungal and antioxidant activity enhancement by substitution with thiosemicarbazide and thiazolidinone moieties. Food Chem 139:488–495CrossRefPubMedGoogle Scholar
  41. Sarkhail P (2014) Traditional uses phytochemistry and pharmacological properties of the genus Peucedanum: a review. J Ethnopharmacol 156:235–270CrossRefPubMedGoogle Scholar
  42. Singh VP, Bali A, Singh N, Jaggi AS (2014) Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 18:1–14CrossRefPubMedPubMedCentralGoogle Scholar
  43. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Munch G (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging 32:763–777CrossRefPubMedGoogle Scholar
  44. Srivastava SK, Ramana KV, Bhatnagar A (2005) Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 26:380–392CrossRefPubMedGoogle Scholar
  45. Takeuchi M, Yamagishi S (2008) Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer’s disease. Curr Pharm Des 14:973–978CrossRefPubMedGoogle Scholar
  46. Thiraphatthanavong P, Wattanathorn J, Muchimapura S, Thukham-mee W, Wannanon P, Tong-un T, Suriharn B, Lertrat K (2014) Preventive effect of Zea mays L. (purple waxy corn) on experimental diabetic cataract. BioMed Res Int.  https://doi.org/10.1155/2014/507435 PubMedPubMedCentralGoogle Scholar
  47. Thomas MC, Baynes JW, Thorpe SR, Cooper ME (2005) The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 6:453–474CrossRefPubMedGoogle Scholar
  48. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31:455–461PubMedPubMedCentralGoogle Scholar
  49. Wada R, Yagihashi S (2005) Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 1043:598–604CrossRefPubMedGoogle Scholar
  50. Wang Z, Ling B, Zhang R, Liu Y (2008) Docking and molecular dynamics study on the inhibitory activity of coumarins on aldose reductase. J Phys Chem 112:10033–10040CrossRefGoogle Scholar
  51. World Health Organization (2016). http://www.who.int/diabetes/global-report/en/
  52. Zhang W, Li Z, Zhou M, Wu F, Hou X, Luo H, Liu H, Han X, Yan G, Ding Z, Li R (2014) Synthesis and biological evaluation of 4-(1,2,3-triazol-1-yl) coumarin derivatives as potential antitumor agents. Bioorg Med Chem Lett 24:799–807CrossRefPubMedGoogle Scholar
  53. Zhao D, Islam MN, Ahn BR, Jung HA, Kim BW, Choi JS (2012) In vitro antioxidant and anti-inflammatory activities of Angelica decursiva. Arch Pharm Res 35:179–192CrossRefPubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2017

Authors and Affiliations

  1. 1.Department of Food and Life SciencePukyong National UniversityBusanRepublic of Korea
  2. 2.Department of Food Science and Human NutritionChonbuk National UniversityJeonjuRepublic of Korea

Personalised recommendations